CME/CE

This program is no longer availble for credit

This Expert Exchange webcast is designed to help improve clinicians’ ability to apply pharmacologic and non-pharmacologic strategies in the management of patients with ADPKD.

Non-small cell lung cancer (NSCLC) is a highly heterogeneous disease, and research has evolved its diagnosis and treatment through the discovery of genetic alterations and molecular pathways, personalizing treatment based on tumor mutation(s). The molecular characterization of tumors using techniques such as next-generation sequencing (NGS) has expanded the understanding of actionable molecular alterations, and in tandem has accelerated the development of drugs to inhibit alterations with greater specificity, leading to the development of novel target-selected agents in NSCLC.

The NCCN Guidelines strongly advise assessment of at least 8 targets for NSCLC by NGS, including MET exon 14–skipping mutations (METex14). The FDA has approved two MET inhibitors, capmatinib and tepotinib, for patients with METex14 metastatic NSCLC, and there is ongoing research for other targeted agents. Studies have established that treatment with MET-targeted therapies improves outcomes in patients with METex14, as opposed to patients receiving chemotherapy and/or immunotherapy, which generate a modest activity response.

AXIS routinely collects and analyzes data gathered from participants in our live activities. These questions provide incredible insight regarding the persistent challenges that clinicians face when trying to optimize treatment and management of patients with cancer to verify where clinical practice gaps exist. That’s why this activity will …

This Expert Exchange webcast is designed to help improve clinicians’ ability to utilize prognostic tools to monitor disease progression and implement appropriate treatment strategies in patients with ADPKD.

This activity is not available for continuing education credit.

By the age of 50, ultrasound imaging demonstrates that 70%-80% of women have fibroids. Uterine fibroids are associated with disability similar to other chronic diseases. They can even lead to lower vitality and social function than are experienced by women with breast cancer. Fibroid-related hysterectomies account for 45% of all US hysterectomies, but a surgical approach is no longer one size fits many. Join Dr. Andrew Kaunitz as he describes the clinical presentations of fibroids and how newly emergent medical options greatly improve fibroid-related symptoms, provide time to consider other alternatives, and can be used to bridge the transition to menopause.

This program is no longer available for credit.

Program Chairman:
Roberto Romero, MD, DMedSci
Chief, Perinatology Research Branch
Division of Maternal-Fetal Medicine and Obstetrics
Division of Intramural Research
NICHD/NIH/DHHS
Editor-in-Chief for Obstetrics
The American Journal of Obstetrics and Gynecology

As the platelet equivalent of hemolytic disease of the fetus and newborn, fetal and neonatal alloimmune thrombocytopenia (FNAIT) is an uncommon yet complex and life-threatening bleeding disorder that results from incompatibility between mother and baby for platelet-specific antigens. Despite relatively normal platelet function, in the setting of severe thrombocytopenia, intracranial hemorrhage is a consequence. Drs. Shulman and Bussel discuss advances in management strategies and concrete steps you can take to lower the risk and stop the progression of this disorder in your patients.

This program is no longer available for credit.

Program Chairman:
Roberto Romero, MD, DMedSci
Chief, Perinatology Research Branch
Division of Maternal-Fetal Medicine and Obstetrics
Division of Intramural Research
NICHD/NIH/DHHS
Editor-in-Chief for Obstetrics
The American Journal of Obstetrics and Gynecology

How well do you understand the biology of hemolytic disease of the fetus and newborn (HDFN)? What about its connection to the FcRn receptor pathway and IgG? Drs. Lee Shulman and Ken Moise go beyond the basics taught in medical school immunology and look more closely at FcRn’s role in protecting IgG. With an improved understanding of these mechanisms, we can expand therapeutic targets beyond the fetus and newborn and finally put the needles away.

This Expert Exchange webcast is designed to help improve clinicians’ understanding of the role radiologic imaging plays in the diagnosis and management of ADPKD.

This activity is not available for continuing education credit.

This program is no longer available for credit.

Program Chairman:
Roberto Romero M.D. D.Med Sci.
Chief, Perinatology Research Branch
Division of Maternal-Fetal Medicine and Obstetrics
Division of Intramural Research
NICHD/NIH/DHHS
Editor-in-Chief for Obstetrics
The American Journal of Obstetrics and Gynecology

Are you taking the right steps to consistently ensure all of your patients at risk of alloimmune disorders of pregnancy, specifically HDFN, receive a helping hand plus timely and appropriate clinical care? Despite having considerable clinical consequences, this area of medicine is not fully understood by many clinicians. Drs. Shulman and Moise provide expert insight on red blood cell alloimmunization, highlighting essential pathophysiology and current and evolving management strategies. Join us to learn new ways to approach this complicated and rare clinical condition.

This Expert Exchange webcast is designed to help improve clinicians’ ability to apply pharmacologic and non-pharmacologic strategies in the management of patients with ADPKD.

This activity is not available for continuing education credit.

Prostate-specific membrane antigen (PSMA) is highly expressed on prostate cancer (PC) cells and can be detected in tumors using positron emission tomography imaging. Even though clinical features predict different stages of PC progression, the application of imaging to guide treatment is still evolving but gaining substantial evidence for the targeting of PSMA. With clinical research shifting paradigms for the treatment of metastatic castration-resistant prostate cancer (mCRPC), novel treatment options require adoption and effective application into clinical practice. PSMA has become an appealing target for diagnostic agents for imaging and therapeutic agents to treat mCRPC. Radionuclide emitters are being used for both cell surface expression of PSMA and the tumor microenvironment, and research has proven the therapeutic efficacy of PSMA-directed radioligand therapy (RLT).

In this educational activity, two experts will examine the role and rationale for PSMA targeted therapies and diagnostics—jointly known as theragnostics—as a revolutionary new approach to treating patients with advanced prostate cancer and will evaluate clinical trial data for PSMA-targeted RLT.